自體免疫疾病治療之展望與規範【醫事綜探】 試閱
Prospects and Management for the Treatment of Autoimmune Diseases
目前從業界到學界皆爭相投入免疫抑制細胞相關研究，希望開發可用於治療自體免疫疾病之藥物與治療方法。惟因該類產品具有複雜性及特殊性，有必要由國家進行相關管理規範，除醫療法、藥事法之規範外，衛生福利部於2017年公告「細胞及基因治療產品管理法」草案，期盼能透過專法管理，提升先進醫療技術及藥品之研發，讓病人能早日獲得完善的治療。
Through medical field to the academic circles, professionals and researchers are urging to invest in immunosuppressive cell-related research, hoping to develop drugs and treatments that can be used to treat autoimmune diseases. However, due to the complexity and particularity of such products, it is necessary for the state to carry out relevant management practices. In addition to the medical and pharmaceutical laws, the Ministry of Health and Welfare announced a draft of the “Cell and Gene Therapy Product Management Act” in 2017. We hope that through the management of specific laws, we will improve the research and development of advanced medical technology and medicines, so that patients can get the best possible treatment immediately.
156-162
